Effects of Fluoxetine on Nogo Expression and Collagen Production with Decrease of Pulmonary Artery

RAN Xun, ZHAO Jian-xun, NIE Hu. et al

Abstract

To investigate the effect of fluoxetine on neurite growth inhibitor (Nogo) expession and collagen production of cardiac tissue in rats with right heart failure and pulmonary hypertension. Methods Thirty one male SD rats were randomly divided into the treatment group，right heart failure group and normal control group. The rats in the treatment group and right heart failure group received intrapertioneal injection of monocrotaline (MCT, 60 mg/kg) to induce pulmonary hypertension and right heart failure. After 21 days, the rats in treatment group were given fluoxetine of 10 mg/（kg·d） by gavage per day for 21 days, the rats in the other two groups were given saline. HE staining was used to observe the pulmonary artery and right ventricular myocardial tissue in rats. The collagen formation in right ventricular myocardium was observed by Masson staining. The expressions of Nogo-A，Nogo-B, typeⅠcollagen and type Ⅲ collagen mRNA in myocardium were measured by real-time fluorescence quantitative PCR, while the semi quantitative measurement of Nogo protein level was detected by Western blot. Results After the intervention of fluoxetine, pulmonary artery stenosis was significantly reduced, myocardial tissue lesion decreased, collagen synthesis decreased in right ventricular myocardium. RT-PCR showed that mRNA of Nogo-A decreased, and mRNA of Nogo-B increased (P<0.05). Western blot showed that the expression of Nogo-A protein decreased, while Nogo-B1 protein expression increased (P<0.05),Nogo-B2 expression was not significantly changed (P>0.05). Conclusion Nogo may affect the collagen synthesis in right heart failure, and partly involved in myocardial fibrosis.

 

Keywords: Fluoxetine, Right heart failure, Nogo, Myocardial fibrosis 

 

Full Text:

PDF


References


MANN DL, BRISTOW MR. Mechanisms and models in heart failure; the biomechanical model and beyond. Circulation,2005,111 (21):2837-2849.

GUIGNABERT C, RAFFESTIN B, BENFERHAT R, et at. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation,200b,111(21) :2812-2819.

MACLEAN MR, DEUCHAR GA, HICKS MN, et al. Overexpression of the 5-hydroxytryptamine transporter gene: effect on pulmonary hemodynamics and hypoxia-induced pulmonary hypertension. Circulation, 2004, 109 ( 17): 2150- 2155.

WANG HM, WANG Y, LIU M, et al. Fluoxetine inhibits monocrotaline-induced pulmonary arterial remodeling involved in inhibition of RhoA-Rho kinase and Akt signalling pathways in rats. Can J Physiol Pharmacol,2012,90( 11); 1506-1515.

ZHUSP, MAO ZF, HUANG J, et al. Continuous fluoxetine administration prevents recurrence of pulmonary arterial hypertension and prolongs survival in rats. Clin Exp Pharmacol Physiol.2009,36(8) ;el-e5[2016-03-25]. http:// onlinelibrary. wiley. com/doi/10. 1111/j. 1440-1681. 2009. 05181. x/abstract; jsessionid =69561A4C354DEB 8E48F2C9A168C65826. f04t02. doi: 10. 1111/j. 1440-1681. 2009.05181. x.

LIU Y, LI M, WARBURTON RR, et al. The 5-HT transporter transactivates the PDGFbeta receptor in pulmonary artery smooth muscle cells. FASEB J, 2007, 21 (11) :2725-2734.

GUILLUY C, EDDAHIBI S, AGARD C, et al. RhoA and Rho kinase activation in human pulmonary hypertension:role of 5-HT signaling. Am J Respir Crit Care Med. 2009, 179 (12) :1151-1158.

YUSUFS, AL-SAADY N, CAMM AJ. 5- hydroxytryptamine and atrial fibrillation; how significant is this piece in the puzzle. J Cardiovasc Electrophysiol,2003,14 (2):209-214.

LEVY FO, QVIGSTAD E. KROBERT KA, et al. Effects of serotonin in failing cardiac ventricle;signalling mechanisms and potential therapeutic implications. Neuropharmacology. 2008,55(6);1066-1071.

BULLARD ТА, PROTACK TL, AGUILAR F, et al. Identification of Nogo as a novel indicator of heart failure. Physiol Genomics,2008,32(2); 182-189.

HARDZIYENKA M. CAMPIAN ME, DE BRUIN-BON R, et al. Sequence of echocardiographic changes during development of right ventricular failure in rat. J Am Soc Echocardiography,2006,19(10):1272-1279.

HADDAD F. COUTURE P, TOUSIGNANT C, et al. The right ventricle in cardiac surgery, a perioperative perspective: H . Pathophysiology, clinical importance, and management. A nest h Analg, 2009,108(2): 422-433.

SCHWARTZ SM, DUFFY JY, PEARL JM. et al. Cellular and molecular aspects of myocardial dysfunction. Crit Care Med,2001 ,29(10 Suppl) ;S214-S219.

COHN JN, FERRARI R, SHARPE N. Cardiac remodeling concepts and clinical implications;a consensus paper from an international forum on cardiac remodeling. Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol,2000,35(3);569-582.

CLARKE M, BENNETT M, LITTLEWOOD T. Cell death in the cardiovascular system. Heart ,2007,93(6):659-664. KRITZ AB, YU J, WRIGHT PL, elal. In vivo modulation of Nogo-B attenuates neointima formation. Mol Ther,2008, 16(11):1798-1804.

PAN JW. ZHENG X, YANG PY. el at. Different expressions of Nogo-Bl and Nogo-B2 in mouse heart microvascular endothelial cell dysfunction induced by lysophosphatidylcholine. Microvasc Res. 2006. 72 ( 1/2): 42- 47.

MI AO RQ, GAO Y. HARRISON KD, elal. Identification of a receptor necessary for Nogo-B stimulated chemotaxis and morphogenesis of endothelial cells. Proc Natl Acad Sci U S A,2006,103(29):10997-11002.


Refbacks

  • There are currently no refbacks.